- Accell Connexus®
- The Accell Process
- The Accell Advantage
- Related documents
Accell Connexus®, Demineralized Bone Matrix Putty
-
Accell Technology
-
Isotis OrthoBiologics Processed DBM
-
30% Poloxamer Reverse Phase Medium Carrier
-
Validated Osteoinductive Potential
-
Poloxamer Reverse Phase Medium
- Thickens at body temperature
- Resists irrigation allowing for better graft containment
- Is inert, biocompatible and safe -
Moldable and easy to pack into virtually any size or shape defect
-
Ready to use
Incorporates:
Benefits:
Available in 0.5, 1, 2.5, 5 and 10cc prefilled syringes
The Accell Process
Lot Division
Each donor lot of DBM is divided in two. Half is reserved for the final formulation.
Solubilization
The remaining half undergoes the Accell process which results in flowable carrier with osteoinductive potential.
Final Formulation
The flowable carrier is then combined with the DBM particles consisting of two components with osteoinductive potential.
E-Beam Sterilization
IsoTis OrthoBiologics terminally sterilizes every lot of Accell product with a low-dose electron beam, a process that has been demonstrated to preserve the osteoinductive potential of bone growth factors.
The Accell Advantage
Skeletally mature sheep model.
Cylindrical 5 mm metatarsal defect created in tibial diaphysis.
Results after 4 weeks
Control - Empty
Minimal bone regeneration observed at 4 weeks. Healing limited to area adjacent to host bone.
1st Generation DBM
Bone regeneration occurs throughout the defect, caused by the presence of osteoinductive DBM particles. The inert carrier has been metabolized.
(DynaGraft II®)
Accell
Significantly more bone formation is evident immediately adjacent to the bone repair surfaces and within the interior of the defect. We believe this occurs because of the immediate access to the BMPs in the Accell products.
(Accell 100™)
Accell documents (pdf):
 |
 |
 |
